Literature DB >> 12021107

The role of Fas ligand in beta cell destruction in autoimmune diabetes of NOD mice.

N Petrovsky1, D Silva, L Socha, R Slattery, B Charlton.   

Abstract

Fas ligand (FasL), a type 2 membrane protein belonging to the TNF family, plays an important role in the induction of cell death. Ligation of Fas receptors by FasL results in apoptosis of the Fas-expressing cell. Autoimmune diabetes results from beta cell destruction by islet-reactive T cells, a process that involves beta cell apoptosis. This raises the question of whether the FasL-Fas pathway plays a major role in beta cell death. To address this issue it is important to know whether beta cells express Fas and/or FasL and, if so, whether induction of these molecules leads to beta cell death. In fact, both Fas and FasL have been demonstrated to be expressed by beta cells in response to cytokine stimulation, although there remains an argument in the literature as to whether beta cells truly express FasL. This is largely because FasL expression has only been demonstrable by immunohistochemistry and not by flow cytometry. Transgenic NOD mice with beta cells expressing a FasL transgene develop an accelerated form of diabetes. We show here that beta cells from FasL transgenic NOD mice are more susceptible to cytokine-induced apoptosis than wild-type beta cells, consistent with the hypothesis that if beta cells express FasL then Fas-FasL interaction on the beta cell surface is able to mediate beta cell self-death in the absence of T cells. Interventions that block the Fas-FasL pathway may be useful, therefore, in the prevention or treatment of type 1 diabetes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12021107     DOI: 10.1111/j.1749-6632.2002.tb02970.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  9 in total

Review 1.  Prospects for the prevention and reversal of type 1 diabetes mellitus.

Authors:  Nikolai Petrovsky; Diego Silva; Desmond A Schatz
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Novel role for RbAp48 in tissue-specific, estrogen deficiency-dependent apoptosis in the exocrine glands.

Authors:  Naozumi Ishimaru; Rieko Arakaki; Fumie Omotehara; Koichi Yamada; Kenji Mishima; Ichiro Saito; Yoshio Hayashi
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

Review 3.  Cellular FLICE-inhibitory protein: an attractive therapeutic target?

Authors:  Olivier Micheau
Journal:  Expert Opin Ther Targets       Date:  2003-08       Impact factor: 6.902

4.  Lentivectors encoding immunosuppressive proteins genetically engineer pancreatic beta-cells to correct diabetes in allogeneic mice.

Authors:  T Kojaoghlanian; A Joseph; A Follenzi; J H Zheng; M Leiser; N Fleischer; M S Horwitz; T P DiLorenzo; H Goldstein
Journal:  Gene Ther       Date:  2008-12-25       Impact factor: 5.250

5.  Contribution of Fas to diabetes development.

Authors:  Alexei Y Savinov; Andrew Tcherepanov; E Allison Green; Richard A Flavell; Alexander V Chervonsky
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-13       Impact factor: 11.205

Review 6.  Vaccine therapies for the prevention of type 1 diabetes mellitus.

Authors:  Nikolai Petrovsky; Diego Silva; Desmond A Schatz
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

7.  Maternal obesity exacerbates insulitis and type 1 diabetes in non-obese diabetic mice.

Authors:  Hui Wang; Yansong Xue; Baolin Wang; Junxing Zhao; Xu Yan; Yan Huang; Min Du; Mei-Jun Zhu
Journal:  Reproduction       Date:  2014-04-01       Impact factor: 3.906

8.  Unraveling the contribution of pancreatic beta-cell suicide in autoimmune type 1 diabetes.

Authors:  Majid Jaberi-Douraki; Santiago Schnell; Massimo Pietropaolo; Anmar Khadra
Journal:  J Theor Biol       Date:  2014-05-14       Impact factor: 2.691

9.  The potential of Fas ligand (apoptosis-inducing molecule) as an unconventional therapeutic target in type 1 diabetes.

Authors:  Abdel Rahim A R Hamad; Kristin Arcara; Sophia Uddin; Thomas Donner
Journal:  Front Immunol       Date:  2012-07-12       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.